share_log

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K: Novo Nordisk A/S - Share Repurchase Programme

诺和诺德 | 6-K:诺和诺德-股票回购计划
美股SEC公告 ·  05/06 17:15
Moomoo AI 已提取核心信息
On May 6, 2024, Novo Nordisk A/S, a leading global healthcare company, announced the initiation of a new share repurchase programme. The programme, which is part of a larger DKK 20 billion repurchase plan for 2024, allows for the buyback of up to DKK 2.2 billion worth of shares. This move is aimed at reducing the company's share capital and fulfilling obligations from share-based incentive programmes. The repurchase of B shares, each with a nominal value of DKK 0.10, will commence on May 7, 2024, and is set to conclude by August 5, 2024. Novo Nordisk has set a cap of 350 million B shares for the repurchase within this period. The company, with a rich history dating back to 1923 and a workforce of approximately 66,000 across 80 countries, is committed to combating serious chronic diseases and has a strong presence in the global market with products available in around 170 countries.
On May 6, 2024, Novo Nordisk A/S, a leading global healthcare company, announced the initiation of a new share repurchase programme. The programme, which is part of a larger DKK 20 billion repurchase plan for 2024, allows for the buyback of up to DKK 2.2 billion worth of shares. This move is aimed at reducing the company's share capital and fulfilling obligations from share-based incentive programmes. The repurchase of B shares, each with a nominal value of DKK 0.10, will commence on May 7, 2024, and is set to conclude by August 5, 2024. Novo Nordisk has set a cap of 350 million B shares for the repurchase within this period. The company, with a rich history dating back to 1923 and a workforce of approximately 66,000 across 80 countries, is committed to combating serious chronic diseases and has a strong presence in the global market with products available in around 170 countries.
2024年5月6日,全球领先的医疗保健公司诺和诺德A/S宣布启动一项新的股票回购计划。该计划是2024年更大的200亿丹麦克朗回购计划的一部分,允许回购价值高达22亿丹麦克朗的股票。此举旨在减少公司的股本,履行基于股份的激励计划规定的义务。每股面值为0.10丹麦克朗的B股的回购将于2024年5月7日开始,并定于2024年8月5日结束。诺和诺德已将此期间的回购上限定为3.5亿股B股。该公司的悠久历史可以追溯到1923年,在80个国家拥有约66,000名员工,致力于抗击严重的慢性病,并在全球市场拥有强大的影响力,产品遍及约170个国家。
2024年5月6日,全球领先的医疗保健公司诺和诺德A/S宣布启动一项新的股票回购计划。该计划是2024年更大的200亿丹麦克朗回购计划的一部分,允许回购价值高达22亿丹麦克朗的股票。此举旨在减少公司的股本,履行基于股份的激励计划规定的义务。每股面值为0.10丹麦克朗的B股的回购将于2024年5月7日开始,并定于2024年8月5日结束。诺和诺德已将此期间的回购上限定为3.5亿股B股。该公司的悠久历史可以追溯到1923年,在80个国家拥有约66,000名员工,致力于抗击严重的慢性病,并在全球市场拥有强大的影响力,产品遍及约170个国家。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息